Menu
Back to User profile » Dr Chang Jiang
Papers published by Dr Chang Jiang:
PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis
Wang F, Wang FH, Sun K, Jiang C, Peng S, Xu LX, Kuang M, Guo GF, Chen SL
Journal of Inflammation Research 2022, 15:6031-6046
Published Date: 31 October 2022
Novel Signatures Based on the Lymphocyte-to-C-Reactive Protein Ratio Predict the Prognosis of Patients with Early Breast Cancer: A Retrospective Study
Wang L, Zhang YL, Jiang C, Duan FF, Yuan ZY, Huang JJ, Bi XW
Journal of Inflammation Research 2022, 15:3957-3974
Published Date: 13 July 2022
A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Early-Stage Breast Cancer
Hua X, Duan F, Zhai W, Song C, Jiang C, Wang L, Huang J, Lin H, Yuan Z
Journal of Inflammation Research 2022, 15:381-394
Published Date: 16 January 2022
Brain metastases in newly diagnosed colorectal cancer: a population-based study
Yang L, He W, Xie Q, Liu S, Kong P, Jiang C, Zhang B, Xia L
Cancer Management and Research 2018, 10:5649-5658
Published Date: 15 November 2018
Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer
Jiang C, Huang Y, Lu J, Yang Y, Rao H, Zhang B, He W, Xia L
Cancer Management and Research 2018, 10:3589-3597
Published Date: 17 September 2018
Proximal shift of colorectal cancer with increasing age in different ethnicities
Yang L, Xiong Z, He W, Xie K, Liu S, Kong P, Jiang C, Guo G, Xia L
Cancer Management and Research 2018, 10:2663-2673
Published Date: 15 August 2018
Association of low skeletal muscle index with increased systematic inflammatory responses and interferon γ-induced protein 10 levels in patients with colon cancer
He WZ, Yang QX, Xie JY, Kong PF, Hu WM, Yang L, Yang YZ, Xie QK, Jiang C, Yin CX, Guo GF, Qiu HJ, Zhang B, Xia LP
Cancer Management and Research 2018, 10:2499-2507
Published Date: 7 August 2018
An increased number of negative lymph nodes is associated with a higher immune response and longer survival in colon cancer patients
He WZ, Xie QK, Hu WM, Kong PF, Yang L, Yang YZ, Jiang C, Yin CX, Qiu HJ, Zhang HZ, Zhang B, Xia LP
Cancer Management and Research 2018, 10:1597-1604
Published Date: 18 June 2018
Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality
Xie QK, He WZ, Hu WM, Yang L, Jiang C, Kong PF, Yang YZ, Yang Q, Zhang HZ, Zhang B, Xia LP
Cancer Management and Research 2018, 10:1365-1375
Published Date: 30 May 2018
A high LDL-C to HDL-C ratio predicts poor prognosis for initially metastatic colorectal cancer patients with elevations in LDL-C
Liao F, He W, Jiang C, Yin C, Guo G, Chen X, Qiu H, Rong Y, Zhang B, Xu D, Xia L
OncoTargets and Therapy 2015, 8:3135-3142
Published Date: 27 October 2015
Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
Yang Q, Yin CX, Liao FX, Huang YY, He WZ, Jiang C, Guo GF, Zhang B, Xia LP
OncoTargets and Therapy 2015, 8:2407-2413
Published Date: 1 September 2015
Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer
Yin CX, Jiang C, Liao FX, Rong YM, Cai XY, Guo GF, Qiu HJ, Chen XX, Zhang B, He WZ, Xia LP
OncoTargets and Therapy 2014, 7:1415-1422
Published Date: 11 August 2014